Skip to content

Study · Animal study (in vivo) · mouse · 1992

1 result

Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha.

Papanastasiou M, Baxevanis CN, Papamichail M

Cancer immunology, immunotherapy : CII1 Jan 1992Cited by 24 (Europe PMC)

PMID1596938 (opens in a new tab)PMCIDPMC11038346 (opens in a new tab)DOI10.1007/bf01741862 (opens in a new tab)PepBankPUB-01596938
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In DBA/2 mice inoculated with L1210 leukaemia cells, a wide range of thymosin alpha‑1 doses had no effect on survival.

    In plain wordsIn mice with leukaemia cells, a wide range of thymosin alpha‑1 doses had no effect.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSurvival of tumour-bearing mice
    Study

    mousen: not reported in source

    DBA/2 mice with syngeneic L1210 leukaemia cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Injections with 150 ng ProT alpha slightly improved the survival of mice whereas higher (500 ng and 1000 ng) doses of ProT alpha and a wide range of thymosin alpha 1 doses remained without any effect.
    1 context sentence
    Summary · context
    The effect of prothymosin alpha (ProT alpha) on the survival of DBA/2 mice inoculated with syngeneic tumour cells was studied.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.